Welcome to our dedicated page for Sagaliam Acquisition news (Ticker: SAGAR), a resource for investors and traders seeking the latest updates and insights on Sagaliam Acquisition stock.
Sagaliam Acquisition Corp. is a blank check company focused on effecting a merger, capital stock exchange, asset acquisition, or similar business combination with one or more entities. The company's subsidiary, Virogentics, is developing therapeutics targeting infectious diseases. Notably, ITV-1 is a patented compound covered by U.S. Patent Nos. 8,066,982 and 7,479,538, showing potential in treating HIV/AIDS and modulating the immune system.
Sagaliam Acquisition Corp. (NASDAQ: SAGA, SAGAU, SAGAR) received a delinquency notification from Nasdaq on April 19, 2023, due to its failure to timely file its Annual Report on Form 10-K for the fiscal year ending December 31, 2022. Nasdaq Listing Rule 5250(c)(1) requires companies to file periodic financial reports with the SEC. The Company has 60 days to present a plan for compliance, with a potential extension of up to 180 days until October 16, 2023, if accepted. Failure to comply could lead to delisting, though the Company may appeal any negative decisions. Sagaliam has indicated it needs more time for its financial statement preparation and auditor completion.
FAQ
What is Sagaliam Acquisition Corp.?
What does Virogentics, a subsidiary of Sagaliam, focus on?
What is ITV-1?
Where is Sagaliam Acquisition Corp. based?
Who is the CEO of Sagaliam Acquisition Corp.?
What is the contact information for Sagaliam Acquisition Corp.?
What are the primary goals of Sagaliam Acquisition Corp.?
What are the key products in development at Virogentics?
What makes ITV-1 unique?
What is the vision of Sagaliam Acquisition Corp.?
